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ABSTRACT 
 
      Forty six patients undergoing renal dialysis participated in this study, 
they Comprise 35 male 11 females admitted to the hospital for 
haemodialysis, and also other twenty persons were admitted as controls. 
      The purpose of this work is compare between the two groups by 
measuring serum triglyceride & cholesterol level. 
       The study pointed out that all the patients of chronic renal failure have 
normal level serum cholesterol. However, the study showed that 43.5% of 
the Patients have serum hyper triglyceridemia. 
 
 
 
 
 
 
 
 
 
 
 
 
 اﻟﺨﻼﺻـــــــــــﺔ
  
   أﺟﺮﻳﺖ هﺬﻩ اﻟﺪراﺳﺔ ﻋﻠﻰ ﺳﺖ وأرﺑﻌﻴﻦ ﻣﺮﻳﻀًﺎ ﻣﻦ ﻣﺮﺿﻰ اﻟﻔﺸﻞ اﻟﻜﻠﻮى ﺗﺤﺖ اﻟﻐﺴﻴﻞ        
                                                              . اﻟﺪﻣﻮى  وذﻟﻚ ﻟﺪراﺳﺔ ﻣﺴﺘﻮى ﺛﻼﺛﻰ اﻟﺠﻠﺴﺮﻳﺪ ىﻮاﻟﻜﻠﺴﺘﺮول ﻓﻰ اﻟﺪم
وﺿﻌﻮا (  ﻣﻦ اﻟﺬآﻮر 53 ﻣﻦ اﻻﻧﺎث و11ﺑﻴﻨﻬﻢ )         ﺗﻀﻢ اﻟﻤﺠﻤﻮﻋﺔ اﻻوﻟﻲ ﺳﺘﺔ وأرﺑﻌﻴﻦ ﻣﺮﻳﻀًﺎ 
  .ﺬت ﻋﻴﻨﺎت ﻣﻦ اﻟﺪم ﻟﻜﻞ اﻟﻤﺮﺿﻰ ﻗﺒﻞ اﻟﻐﺴﻴﻞأﺧ. اﻟﻐﺴﻴﻞ اﻟﺪﻣﻮي ﻣﺮﺗﻴﻦ ﻓﻲ اﻻﺳﺒﻮع  ﺗﺤﺖ
أﺧﺬت (  ﻣﻦ اﻟﺬآﻮر 53 ﻣﻦ اﻻﻧﺎث و11ﺑﻴﻨﻬﻢ ) ﺷﺨﺼًﺎ ﺳﻠﻴﻤًﺎ 02ﺿﻤﺖ اﻟﻤﺠﻤﻮﻋﺔ اﻟﺜﺎﻧﻴﺔ         
  . ﻣﻦ اﻟﺪم ﻟﻜﻞ ﻣﻨﻬﻢ ﻋﻴﻨﺎت
        اﻟﻐﺮض ﻣﻦ اﻟﺪراﺳﺔ هﻮ اﻟﻤﻘﺎرﻧﺔ ﺑﻴﻦ اﻟﻤﺠﻤﻮﻋﺘﻴﻦ ﻟﻤﻌﺮﻓﺔ ﻣﺴﺘﻮى ﺛﻼﺛﻰ اﻟﺠﻠﺴﺮﻳﺪ واﻟﻜﻠﺴﺘﺮول 
 ﻣﺴﺘﻮى اﻟﻜﻠﺴﺘﺮول ﻓﻰ دم اﻟﻤﺮﺿﻰ واﻷﺻﺤﺎء وأﻇﻬﺮت اﻻﺧﺘﺒﺎرات أن ﻧﺴﺒﺔ أﺧﺘﺒﺮ  اﻟﺪم ﻓﻰ
ﻓﻰ اﻟﺪم ﻃﺒﻴﻌﻴﺔ ﻓﻰ آﻞ ﻣﺮﺿﻰ اﻟﻔﺸﻞ اﻟﻜﻠﻮى ﻣﻘﺎرﻧﺔ ﻣﻊ اﻷﺷﺨﺎص اﻷﺻﺤﺎء ﺑﻴﻨﻤﺎ ﻧﺴﺒﺔ  اﻟﻜﻠﺴﺘﺮول
  .ﻣﻦ اﻟﻤﺮﺿﻰ ﻣﻘﺎرﻧﺔ ﻣﻊ اﻷﺷﺨﺎص اﻷﺻﺤﺎء% 5.34ﻣﺮﺗﻔﻌﺔ ﺑﻨﺴﺒﺔ  ﺛﻼﺛﻰ اﻟﺠﻠﺴﺮﻳﺪ
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CHAPTER ONE 
 
INTRODUCTION 
 
Animal's in vivo and in vitro data suggests that dyslipidemia plays an 
important role in the initiation and progression of chronic renal disease, but 
few prospective studies have been conducted in humans. The treatment of 
these lipid abnormalities may decrease the incidence of early disease. More 
recently, it has been suggested that dyslipidemia may contribute to 
accelerated development of renal insufficiency. Although there is substantial 
animal evidence supporting a causal relationship between lipid levels and 
the development of glomerular injury leading to glomerulosclerosis, human 
data are sparse. To date, most prospective studies of lipids and renal disease 
have focused on the progression of established renal disease rather than renal 
disease initiation. Therefore, little information is known about the 
prospective relationship between lipids and declines in renal function among 
persons with normal renal function. Such information is necessary to 
identify modifiable risk factors that predict development and progression of 
renal disease. 
In Sudan there has been an increase in the incidence of renal diseases 
in the past decade and a concomitant increase in kidney failure patients. 
Renal dialysis was found to be a leading therapy in end stage renal disease. 
This study is a trial to determine the association of plasma lipids with loss of 
renal function and clinical symptoms of mild renal insufficiency. The study 
is concerned with investigating the disorder of blood lipids that plays an 
important role in the progression of chronic renal disease to dialysis in 
chronic renal failure (CRF) patients. 
Objectives 
The present work is undertaken in order to gain essential information 
about the importance and clinical significance of lipids in patients with 
chronic renal failure under haemodialysis. To satisfy the objectives, the 
study is presented into three parts:- 
1. Study of renal failure disease. 
2. The importance of abnormality of lipids in patients with chronic 
renal failure. 
3. The clinical diagnosis of patients and clinical conditions suggesting 
the use of haemodialysis. 
 
 
CHAPTER TWO 
 
LITERATURE REVIEW 
 
 
2.1 Anatomy of the Kidney: 
 
In humans, the kidneys are a pair of bean-shaped organs located at the 
back of the body about the level of the waist. Each kidney measures 10-15 
cm in length and weights approximately 160 gms. The kidney is made up of 
about one million functioning units, called nephrons. Each nephron is made 
up of a glomerulus, proximal tubule, loop of Henle, distal tubule and 
collecting duct. The tubule is a tubelike structure, the closed end of the 
tubule forms a cup shaped structure called the glomerular capsule which 
surrounds a network of tiny blood vessels called the glomerulus, (Smith et 
al. 1999). The general anatomy of the human kidney is presented in figure 
(1). 
Arterial blood is supplied to the kidney via the renal arteries, which 
branch off the abdominal aorta, and venous blood is conveyed to the interior 
vena cava via the renal veins. Approximately 25% of humans possess dual 
or multiple renal arteries on one or both sides. The left renal vein is longer 
than the right and for this reason the left kidney, where possible, is usually 
chosen for live donor transplant nephrectomy. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure (1) Section of the human kidney showing the measuring vessels that 
supply the blood flow to the kidney and schematic of the microcirculation of 
each nephron (Guyton, 2001) 
The collecting duct merges in the inner medulla to form the ducts of 
Bellini, which empty at the apices of the papiallae into the calyces. The 
collecting ducts drain into a common funnel shaped sac called the kidney 
pelvis located on the hollow side of the kidney. The ureter connects the 
kidney pelvis with the bladder. 
The glomerulus comprises three main cell types: 
1. Endothelial cells which are fenestrated with 500-1000 A 0 pores. 
2. Epithelial cells, visceral and parietal. 
3. Mesangial cells. 
The mesangial cells are believed to be related to macrophages of the 
reticuloendothelial system and have a phagocytic function. They also secrete 
the mesangial matrix of the glomerulus. The glomerular capillary basement 
membrane lies between the endothelial and the visceral epithelial cells. 
Together the endothelial cells, basement membrane and epithelial cells form 
the filtration barrier or sieve (Kumar and Clark, 2003). 
The renal tubules are lined by epithelial cells, which are cuboidal 
except in the thin limb of the loop of Henle where they are flat. Proximal 
tubular cells differ from other cells of the system in possession of a luminal 
brush border. The cortical portion of the collecting tubules contains two cell 
types with different functions. This anatomical arrangement is such as to 
allow changes in the renal tubule to influence behavior of adjacent 
glomerulus. 
2.2 Renal Function: 
 
The vital function of the kidney is to remove toxic and waste products 
and excess water from the body. The other functions of the kidney are to 
maintain the body's balance of various salts such as sodium, potassium, 
calcium, and phosphate as acid. The kidney is also a producer of hormones. 
For example erythropoietin is responsible for stimulating production of red 
blood cells in the bone marrow, while active vitamin D is necessary for 
strong healthy bones (Smith et aI, 1999). 
The kidneys have a unique system involving the free ultra filtration of 
water and non-protein-bound, low-molecular-weight compounds from the 
plasma and the selective reabsorption and/or excretion of these as the ultra 
filtrate passes along the tubule. 
An essential feature of the renal function is that a large volume of 
blood, 25 % of cardiac output or approximately 1300 ml per minute, passes 
through the two million glomeruli (Kumar and Clark, 2003). 
A hydrostatic pressure gradient of approximately 10 mmHg (a 
capillary pressure of 45 mmHg minus 10mm Hg of pressure within 
Bowman's space and 25mm Hg of plasma oncotic pressure) provides the 
driving force for ultra filtration of virtually protein-free and fat-free fluids 
across the glomerular capillary wall into Bowman's space and so into the 
renal tubule. 
The ultra filtration rate (glomerular filtration rate; GFR) varies with 
age and sex but is approximately 120-130 mL /min 1.73 m2 surface area in 
adults. The need for this high filtration rate relates to the elimination of 
compounds present in relatively low concentration in plasma (e.g urea). 
Thus 60-80% of filtered water and sodium are reabsorbed in the proximal 
tubule along with virtually all the potassium, bicarbonate, glucose and amino 
acids. Further water and sodium chloride are reabsorbed more distally and 
fine tuning of salt and water balance is achieved in the distal and collecting 
tubules under the influence of aldosterone and antidiuretic hormone (ADH). 
The final urine volume is thus 1-2 L daily. Calcium, phosphate and 
magnesium are also selectively reabsorbed in proportion to the need to 
maintain a normal electrolyte composition of body fluids (Kumar and Clark, 
2003). 
The urinary excretion of some compounds is more complicated. For 
example, potassium is freely filtered at the glomerulus, almost completely 
absorped in the proximal tubule, and excreted in the distal tubule and 
collecting ducts. Other compounds filtered and reabsorped or excreted to a 
variable extent, they include urate and many organic acids, including many 
drugs or their metabolic breakdown products. Penicillin and cefradine are 
examples of compounds secreted by the tubules. 
Urine is concentrated by a complex interaction between the loops of 
Henle, the medullary interstitium, medullary blood vessels (vasa recta) and 
the collection tubules. Tubular function is also critical to the control of acid-
base balance. Thus filtered bicarbonate is largely reabsorbed and hydrogen 
ions are excreted are mainly buffered by phosphate (Kumar and Clark, 
2003). 
 
2.2.1 Glomerular Filtration Rate (GFR) 
 
In healthy people the GFR remains remarkably constant owing to 
intrarenal regulatory mechanisms. In disease, with a reduction in intrarenal 
blood, flow, damage on loss of glomeruli, or obstruction to the free flow of 
ultra filtrate along the tubule, the GFR will fall and the ability to eliminate 
waste material and to regulate the volume and composition of body fluid 
will decline. This will be manifested as a rise in the blood level of urea or 
the plasma level of creatinine and in a reduction in measured GFR (Kumar 
and Clark, 2003). 
2.2.2 Tubular Function: 
 
The major function of the tubule is the selective reabsorption or 
excretion of water and various cations and anions to keep the volume and 
electrolyte composition of body fluid normal. 
The active reabsorption from the glomerular filtrate of compounds 
such as glucose and amino acids also takes place. Within the normal range 
of blood concentrations these substances are completely reabsorbed by the 
proximal tubule. However, levels are elevated above the normal range, the 
amount filtered (filtered load = GFR * plasma concentration) may exceed 
the maximal absorptive capacity of tubule and the compound 'spills over' 
into the urine. Examples of this occur with hyperglycaemia in diabetes 
mellitus or elevated plasma phenylalanine in phenylketonuria (Kumar, 2003; 
Smith, 1999). 
2.3 Renal Disease: 
 
Renal disease is a disease of the kidney that alters the structure and 
function of the kidney. There are many diseases of the kidneys such as renal 
failure glomerulonephritis, pylonephritis, and polycytic kidney and lupus 
nephritis. The treatment and potential for recovery depends on the type of 
disease. Kidney disease can lead to renal failure. 
Symptoms and signs of renal disease include burning sensation during 
urination, frequent urination at night, passing blood-stained urine, puffiness 
around eyes, swelling of hands and feet, pain in the lower back area just 
below the ribcage and high blood pressure. If these symptoms are present 
further investigation need to be carried to find out the cause, there may not 
be any obvious signs at all and the clue to kidney disease may be abnormal 
urine finding picked up on urine tests alone. 
2.3.1. Renal Failure: 
 
Renal failure is a condition where the kidneys are incapable of 
performing their normal functions. Certain toxic substances, which should 
have been excreted such as urea and creatinine, accumulate in the body. 
These levels, if high enough, cause symptoms such as tiredness, weakness, 
loss of appetite and vomiting. Creatinine is the break down product of 
muscle and the blood creatinine is often used as a measure of the degree of 
kidney failure. Generally, when the creatinine levels in the blood reach a 
level of 900 U mole /L the patient is put under dialysis. 
In renal failure, the volume of water in the body increases resulting in 
swelling of tissue. Excess salt and water retention may result in high blood 
pressure, swelling of the legs, face and abdomen. The kidney fails to excrete 
phosphate causing the blood phosphate level to increase and calcium level to 
fail. This results in bone disease and may predispose the patient to fractures 
of the bones. The bone problem is also made worst by a lack of active 
vitamin D, and inadequate production of erythropoeitin leads to anemia. 
a) Causes of renal failure: 
 
The common causes of kidney failure are glomerulonephritis 
(inflammation of the kidney) and diabetes mellitus. Also the causes of 
kidney failure are presence of stones, polycystic kidneys, systemic lupus 
erythrematosus, uncontrolled hypertension and use of certain drugs. 
b) Symptoms of kidney failure: 
 
In mild renal failure, no symptoms are present. However, renal tests 
show some abnormalities, as renal failure worsens the patient has pale and 
sallow complexion, easy fatigueability, shortness of breath, body itch, poor 
appetite, sometimes accompanied with nausea and vomiting, swelling of the 
face and legs, frequent urination at night and passing little urine. The 
measures to slow down the rate of kidney failure include control to blood 
pressure and control of diet: 
Strict control of blood pressure is necessary as high blood pressure 
damages the kidney. This requires observation of low salt diet and high 
blood pressure medications. The intake of proteins such as in poultry, 
seafood and Soya products helps to reduce the pressure within the kidneys 
and therefore protects the kidney. However, caution is taken not to reduce 
this to too Iow level, or malnutrition will result. 
Reduction of the salt content in sauces and seasonings is 
recommended as well. Excessive fluid and salt contribute to hypertension. 
Fluid allowance for the day depends on the fluid status of the patient. It may 
be restricted to a range of 500 mL to 300 mL a day. 
Kidney failure patients are advised to restrict intake of high potassium 
food such as leafy vegetables, fruits and fruits juices. A high blood 
potassium level may cause the heart to stop beating. Beans, peas, 
mushrooms, nuts, milk, soya products and legumes contain phosphates and 
should be avoided. Retention of phosphate in the blood (due to the failure of 
the kidney to excrete it) results in the lowering of the blood calcium leading 
to bone disease. 
Medications specific to different kidney disease may be prescribed 
depending on the cause of the kidney failure. These may include preventive 
antibiotics, dipyridamole, warfarin and steroids. Beside blood pressure 
medications, doctors may prescribe other medications. The common 
medications are multivitamins, calcium supplements and phosphate binders. 
This is to bind phosphate in the gut and prevent  
excessive absorption of phosphate, which can cause bone disease. Some of 
those are calcichew or aluminum containing compounds such as 9 altemagel 
and Alutabs Wilson and Wain, 1992). 
2.3.2. Types of Renal failure: 
 
2.3.2.1 Acute Renal failure: 
 
Acute renal failure (ARF) is a complex disease resulting from acute 
reduction in, or cessation of, renal function and is characterized by an urea 
or oligouria (less than 180 ml / M2 / 24 hr of urine) electrolyte and acid-base 
disturbances (notably hyper-kalemia and metabolic acidosis) and impaired 
excretion of substances such as creatinine, urea and phosphate. Reduction in 
urine volume, however, is not an essential feature of acute renal failure and 
the other features can be present during  
a urine output in excess of 350 mL / M2 /24 hr. This condition is known as 
acute non-oliguria renal failure. 
a- Etiology: 
 
A large number of unrelated clinical conditions which damage or 
interfere with the function of one or more of the structure or functional units 
of the kidney may cause acute renal failure. In addition to those, chronic 
renal disease may be as acute renal failure. 
b- Pathophysiology: 
Acute renal failure may be classified as pre- renal, intrinsic renal or 
post renal in origin. Pre- renal failure is characterized by oliguria. The 
reduction in urine volume and retention of waste products is dependent on 
reduction in effective plasma volume or on decreased cardiac output, e.g. in 
congestive heart failure, the renal response is a physiological adaptation to 
these changes. The urine concentration of sodium is low; usually less than 
20 m .Eq / L, and the urea concentration and osmolality are high. The urine 
volume increases following correction of the underlying disorder. Severe or 
prolonged contraction of intravascular volume may lead to intrinsic renal 
damage. 
In acute intrinsic renal failure, when the principal of site injury is the 
renal tubule, the urine concentration of sodium is often elevated to 50 to 100 
m. Eq/L; when glomercular injury predominates and tubular function is 
intact, a urine sodium concentration less than 40 m. Eq/L may be expected. 
The urine volume is usually low or nil, although a non-oliguric form of acute 
renal failure may develop following  trauma or exposure to nephrotoxins .In 
classic acute intrinsic renal failure resulting from tubular damage, the course 
may be divided into 3 stages: a nurio or oliguric, diuretic and convalescent, 
the management of these stages differs. In children this sequence often does 
not occur. 
Acute post-renal failure results from obstruction of urine flow at some 
point in the pelvicalyceal collecting system or in the ureters. Causes of 
obstruction include renal calculi, crystal formation during sulfonamide 
therapy and trauma responsible for blood clots. 
Hyperkalemia develops because of decreased renal excretion of 
potassium in conjunction with cellular release of potassium as a result of 
trauma, hemolysis, infection, or hypoxia. Metabolic acidosis, which is often 
present in acute renal failure, also leads to increased plasma K+  
concentration. Because of an intracellular shift of H+ in exchange for K+ the 
cardio-toxic effects of hyperkalemia result from a decreased ratio of intra 
cellular to extra cellular K+ . 
Hyponatremia in acute renal failure is the result of dilation of body 
fluids as a consequence of excessive intake of water relative to that of 
sodium. Metabolic acidosis, with or without increased plasma H+ 
concentration (acidemia) is common in acute renal failure and is the 
consequence of impaired ability of the kidney to eliminate acid during 
increased production of acid radicals in the catabolic state. 
The blood pressure may be normal or reduced. Depending on the 
underlying cause of acute renal failure, acute hypertension may be a major 
threat; it may result in hypertensive encephalopathy, or it may aggravate 
circulatory congestion. It is common in acute post- streptococcal 
glomerculonephritis and may occur in other conditions, such as the 
hemolytic uremic syndrome,  and acute obstructive nephropathy; any of 
these may lead to acute renal failure. 
Blood urea nitrogen, plasma creatinine and uric acid concentrations 
are elevated because of reduced excretion. Anemia, thrombocytopemia, 
leukocytosis, impaired carbohydrate tolerance and hyperlipidemia may also 
occur in acute renal failure. 
c- Clinical Manifestations: 
The clinical pattern of acute renal failure is often overshadowed by 
the manifestations of the precipitating cause. For example the patient may be 
in shock as a result of endotoxemia, severely dehydrated with gastroenteritis, 
jaundiced with carbon tetrachloride poisoning or having seizures related to 
the hypertensive encephalopathy of acute glomerulonephritis. In the initial 
assessment, attention must be paid to the possibility that one or more of the 
following precipitating or associated findings may be present: shock, trauma, 
hemolysis, sepsis, dehydration, intoxication, hemorrhage, hypertension, 
cardiac anahyemia secondary to hyperkalemia circulary congestion, 
metabolic acidosis, congestive renal failure pelvicalyceal or uretral 
obstruction or underlying or precoasting chronic renal disease. 
The clinical features related more specifically to acute renal failure 
include decreased urinary output (oliguria to anuria), edema, drowsiness, 
and the cardiac arrhythmia of hyperkalemia, circulatory congestion and 
tachypnea as a result of metabolic acidosis In acute renal failure of acute 
post-streptococcal glomerculonephritis, complete recovery is the rule, 
provided the electrolyte and acid-base disturbances, circulatory congestion 
and hypertensive complications are managed satisfactorily (Vaughaw,1981). 
d. Diagnosis: Detection of failure bv Renal Function Test: 
The diagnosis of kidney disease, to a great extent is made in clinical 
chemistry laboratories. The kidney function tests when properly conducted 
can give valuable information about the status of kidney function and 
frequently about the location of the defect. However, the kidney has a 
considerable functional reserve and these tests may be normal even in the 
presence of relatively severe renal pathology. These tests can be separated 
into the following groups: - 
Group 1 Test: 
1. Blood urea nitrogen. 
2. Serum creatinine. 
3. Routine urine examination. 
Group 11 Tests: 
1. Serum total protein, albumin and globulins. 
2. Quantitative determination of urinary proteins. 
3. Electrophoretic fractionation of serum proteins. 
4. Serum cholesterol. 
Group III Tests: 
Tests measuring glomerular filtration 
1. Creatinine clearance test. 
2. Urea clearance test. 
Group 1V Tests: 
Tests measuring tubular function 
1. Determination of specific gravity, concentration and ability of 
kidney. 
2. Determination of serum and urine osmolarity. 
3. Phenosulphonphthalein (PSP) test. 
Group V Tests: 
Tests determining acid-base status 
1. Serum electrolytes (sodium, potassium and chlorides) 
1. Serum inorganic phosphorus and calcium. 
2. Serum bicarbonate. 
4. Blood gases (P02, CO2) and blood PH (Smith et aI, 1999). 
e- Laboratory data: 
The usual abnormal changes accompanying acute renal failure include 
hyperkalemia, hypematremia, metabolic acidosis, elevation of serum 
concentrations of urea, phosphate, uric acid and creatinine, hypocalcaemia 
and anemia. The urine may contain red blood cells, protein, casts and tubular 
cells. The urinary concentrations of sodium is usually low (< 20 m.Eq/L) in 
pre-renal acute renal failure and in failure owing to glomerular disease, and 
elevated (70 to 90 m. Eq/L) in tubular disorders. Electro-cardiographic 
changes indicative of hyperkalemia may be present. In nonoliguric acute 
renal failure, the urine sodium concentration is usually lower and the 
osmolarity higher than in acute oliguric intrinsic renal failure. 
2.3.2.2. Chronic Renal Failure (chronic uremia): 
Chronic Renal Failure (CRF) is a complex of clinical chemical and 
metabolic disturbances that result from permanent reduction in renal 
function. The essential feature of which is a decreased glomerular filtration 
rate (GFR). Clinical problems are usually not evident until the GFR is below 
20 mL /min JM2. In preadolescent children with a GFR at this level, blood 
urea nitrogen is usually above 40 mg /dL and the serum creatinine is over 
1.6 mg dL. The normal GFR in children over one year of age is 70+5 (IS.D) 
mL /M2/min (Vaughaw, 1981). 
a- Etiology: 
There is now good evidence that essential hypertension is caused by 
renal genetic mechanisms and that the propensity for the development of 
renal disease in response to renal injury may also, and separately, be partly 
genetically determined. CRF develops in about 30% of type 1 and type 11 
diabetics, with a peak incidence at about 15 years after the development of 
diabetes mellitus. Predictors of the development of diabetic 
glomerulosclerosis are hypertension, poor glycemic control, 
microalbuminuria and the development of proliferative renal vascular 
disease. The drug choice for diabetic patients with hypertension and lor 
microalbuminuria or fixed proteinuria is an angiotensin-converting enzyme 
(ACE) inhibitor. Even after fixed albuminuria has developed, ACE 
inhibitors can markedly delay progression of the decline in the glomerular 
filtration rate (GFR) to about 2 mL/ minute /year. Untreated, the GFR in 
diabetic glomerulosclerosis progresses downward at a rate of about 10 to12 
mL/minute / year. 
Evidence is increasing that micro albuminuria (>30 mg 124 hours) is a 
harbinger of hypertensive nephrosclerosis and some may diminish that 
progression to a fixed albuminuria, but probably not all, anti hypertensive 
drugs. Microalbuminuria is certainly well documented as a cardiovascular 
risk factor, and that alone justifies intensifying antihypertensive treatment in 
such patients It has not yet been established whether normalization of blood 
pressure can delay or stop progression once the serum creatinine 
concentration is elevated and /or fixed albuminuria has developed. Nor it is 
as yet known which is the best antihypertensive to use in such clinical 
circumstances. 
b- Pathophsiology of chronic renal failure: 
Regardless of the primary cause of nephron loss, some usually survive 
or are less severely damaged. These nephrons then adapt and enlarge, and 
clearance per nephrons markedly increases. If the initiating process is 
diffuse, sudden, and severe, such as in some patients with rapidly 
progressive glomerulonephritis (crescentic glomerulonephritis), acute or sub 
acute renal failure may ensue with the rapid development of end stage renal 
disease (ESRD). In most patients however, disease progression is more 
gradual and nephron adaptation is possible. Other mechanisms of 
progression that are probably important in the sclerosis of adapted glomeruli 
include glomerular coagulation, hyperlipidemic effects, and mesangial cell 
proliferation. 
The pathophysiology of focal glomerulosclerosis has been compared 
with that of atherosclerosis. It is likely that tublointerstitial fibrosis 
contributes to nephron failure in the process of nephron adaptation. This 
result is in part secondary to the potential of protein-uria to cause proximal 
tubule atrophy; the release of transforming growth factor B, endotheline and 
angiotensin 11 secondary to tubular injury and nephron ischemia is 
secondary to arteriosclerosis. 
This process of nephron adaptation has been termed the "final 
common path". The ability of nephrons to adapt by enlarging and increasing 
function has beneficial effects in maintaining whole kidney GFR, as well as 
rates of sodium potassium, phosphate acid, and solute excretion, especially 
the products of protein metabolism that cause the uremic syndrome. Adapted 
nephrons enhance the ability of the kidney to postpone uremia, but 
ultimately the adaptation process leads to the demise of these nephrons. 
If these processes are, initially at least, important in postponing 
ESRD, it is clear that monitoring renal function only by changes in serum 
creatinine is, at the least insensitive to nephron dropout because whole- 
kidney GFR can be maintained by increasing single nephron GFR in 
surviving adapted nephrons. Quantitation of urinary protein excretion, the 
use of urinary microscopy, and perhaps in the future, measurement of 
potentially harmful and blood cytokines may all be important (Goldman, 
2000). 
Chronic renal failure is thus associated with progressive loss of the 
ability of the kidney to maintain a constant internal environment in the face 
of substantial changes in solute intake. Adapted nephrons have not only an 
enhanced GFR but also enhanced tubular functions in terms of, for example, 
potassium and potassium secretion. If an ion is normally controlled by 
varying reabsorption, as with sodium, reabsorption is minimized, and if it is 
controlled by secretion, as with potassium, secretion is maximized and may 
lead to excretion that exceeds the filtered rate. 
It is likely that the growth factors responsible for hypertrophy of 
nephrons also eventually lead, after chronic dialysis for some years, to 
acquired renal cyst formation; these cysts are believed to be pre-malignant. 
 
c- Clinical Manifestations: 
Patients are often not seen until late in the course of the disease, when 
much of their kidney function has already been lost. All CRF patients with 
the exception of those with medullary cystic kidney disease have fixed 
protein urea (>200 mg /2 hours). Because many transient and benign cause 
of proteinuria are possible, population screening is not justified at present. 
Insurance companies in developed countries, however, routinely require 
testing for proteinuria because of the morbidity and mortality associated 
with CRF. The syndrome may also come to attention because of an elevated 
blood urea nitrogen (BUN) or serum creatinine concentration in laboratory 
testing done for a variety of reasons. Only usually is CRF initially 
manifested by urinary tract symptoms, and most patients with such 
symptoms as dysuria, frequency, and polyuria do not have CFR. 
Occasionally, patients with primary tubulo-interstitial disease may have 
polyuria and nocturia because impaired renal concentrating ability is an 
early feature secondary to predominant damage to the renal medulla. 
Hypertension develops in 95% of patients with CRF before ESRD 
does, and 5% of all hypertensive subjects have an elevated blood pressure 
secondary to CRF or underlying kidney disease before the development of 
azotemia. (Azotemia means an elevation of BUN above normal, but uremia 
implies the presence of symptoms secondary to renal nitrogen retention). 
Initial presentation of patients who already have features of CRF such 
as uremic symptoms is common because the kidney adapts so well to 
progressive loss of nephrons and can maintain constancy of the internal 
environment until about 75% of renal function has been lost. Initial 
misdiagnosis is common, especially for anemic, gastrointestinal, 
cardiovascular manifestations. In some specific renal diseases, other 
symptoms may call the causative disease into question (Goldman, 2000). 
d- Laboratory data: 
The essential features of chronic renal failure are  reduction in GFR as 
shown by decreased insulin, iothalamate or creatinine clearance and 
elevation of the blood urea nitrogen and serum creatinine concentration. 
The extent of reduction in GFR is the major determinant of the 
severity and of the extent to which other abnormal changes occur, such as 
hyperphosphatemia, hypocalemia, metabolic acidosis, hyperkalemia, 
hypoproteinemia, normochromic anemia, reduced platelet adhesiveness, 
prolonged bleeding time and isosthenuria. Depending on the cause of 
chronic renal failure, there may be renal salt wasting, proteinuria and / or 
abnormal urinary sediment. 
e- Diagnosis and Differential Diagnosis: 
It is essential to establish the nature of the underlying disease leading 
to the chronic renal failure. Conditions that may aggravate a pre-existing 
state of chronic renal insufficiency include: congestive heart failure and 
uncontrolled hypertension; hypovolemia resulting from gastrointestinal or 
urinary losses related to diuretic therapy or impaired ability to conserve fluid 
and electrolytes in the face of inadequate intake; infection of the urinary 
tract, obstruction by calculi stomal closure or uric acid nephropathy; 
disturbances in concentrations of plasma electrolytes, e.g. hypercalcemia or 
hyperkalemia, which lead to impaired renal function and nephrotoxicity 
caused by drugs or other exogenous agents. 
f- Prevention: 
With proper therapy, a high proportion of children with chronic renal 
failure need never reach the stage of advanced renal insufficiency that 
requires haemodialysis and renal transplantation to prolong life. In this 
context some of the following must be considered:- proper antibacterial 
agents for treatment of urinary tract infections, voidance or cessation of use 
of nephrotoxic drugs, use of corticosteroid or cytotoxic drugs in specific 
glomerular diseases, prevention and treatment of nephrocalcinosis or 
urolothiasis in renal tubular acidosis, hyperuricemia and cystinuria, 
diagnosis and treatment of  bstructive uropathy and control of hypertension. 
g- Treatment: 
Management of chronic renal failure demands not only an 
understanding of the complex physiological disturbances and the necessary 
skills in diagnosis and treatment but as importantly, an awareness of and 
sensitivity in dealing with the tremendous impact that chronic progressive 
renal disease has on the patient and the family. 
Resources of personnel other than the physician, such as nurses, social 
workers, dieticians, teachers and psychiatrists are important in providing the 
assistance and guidance that may be needed to deal effectively with these 
problems. Features are applicable to most patients regardless of the 
underlying disorder. 
Blood pressure should be maintained within the normal range, but at 
times an elevation of 10 to 15 mmHg in diastolic pressure may have to be 
accepted. Conservative measures using standard anti hypertensive agents 
with or without sodium restriction, depending on whether there is edema, are 
usually successful. Flydrochlorothiazide in combination with hydralazine are 
used as initial therapy. Proprandol is also a useful drug in combination with 
hydro chlorathiazide and/or hydralazine. Strict restriction of sodium to a 
level of 5 to 10 mEq/24hrs may be necessary in severely oliguric 
hypertensive patients. 
Cardiac failure requires skillful balancing of several types of therapy. 
These include reduction of blood pressure to normal and increasing the 
hemoglobin concentration to 8 to 9 gm slowly by small transfusions of 
washed, packed red blood cells and decreasing circulatory congestion by 
restriction of salt and fluid and the use of diuretics such as furosemide and 
judicious use of digoxin. Since digoxin is largely excreted by the kidney, the 
dose is reduced in chronic renal failure. When cardiac become life 
threatening and is not amenable to conservative measures, consideration 
must be given to instituting peritoneal dialysis or haemodialysis. 
Circulatory congestion is best treated by rigid restriction of intake of 
sodium and fluids and by oral or parenteral administration of furosemide. 
The problems of hypertension, cardiac de-compensation and 
circulatory congestion are interrelated in their pathogenesis, as are the 
therapeutic measures used in their treatment. Improvement in one of these 
circulatory problems by a single treatment measure is often accompanied by 
parallel improvement in the others. 
Treatment of Renal Osteodystrophy is an essential part in chronic 
renal failure patients. The principal measures for prevention and treatment 
are restriction of dietary phosphorous, administration of aluminum 
hydroxide gel to bind phosphorous, in the intestine, provision of 
supplemental calcium, provision of vitamin D or dihydrotachysterol, control 
of metabolic acidosis and provision of a nutritious diet. 
Radical measures such as parathyroidectomy to treat hyper 
parathyroid bone disease are seldom required. If the plasma phosphorous is 
elevated, calcium supplementation and vitamin D are used judiciously so 
that a gradual elevation of plasma calcium to normal is achieved. Metastatic 
calcification is considered as a potential complication when vitamin D and 
calcium supplements are given to a uremic patient (Vaughaw, 1981). 
Treatment of anemia is another path in chronic renal failure. It is 
unwise to attempt to keep the hemoglobin at normal level by repeated 
transfusions. If the hemoglobin level is below 6 gm, the danger of cardiac 
de-compensation makes it reasonable to give small (20 to 75 mL) 
transfusions of fresh packed, washed red blood cells to raise the hemoglobin 
to 7 to 8 gm percent. Caution is exercised to avoid circulatory overload 
during the transfusion; it is sometimes necessary to withdraw an equivalent 
volume of blood from the patient. 
A normal intake of dietary iron should be assured to avoid iron 
deficiency; Erythropoiesis may be improved by treatment of underlying 
infections, regular dialysis and proper nutrition. 
h- Drug Dosage in Chronic Renal Failure: 
If the dosage of drugs excreted by the kidney is not reduced or the 
intervals between administrations of them lengthened during impaired renal 
function, retention of them or their metabolites may result in high blood and 
tissue concentrations that may have deleterious effect. Should the drug be 
potentially nephrotoxic, the risk of increasing the degree of renal 
insufficiency is an extremely serious one. The question of drug dosage is 
complex and a complete discussion cannot be given here, the dosages and 
the interval of their administration must therefore be modified in chronic 
renal failure is to measure either the rate of disappearance from the plasma 
following a single dose and thus establish the half-life of the drug, or to 
determine the plasma concentration in order to know if a safe and 
therapeutic level is present. For most drugs, however, this is not practicable 
and modification in dosage is based on an "educated guess" which takes into 
account the degree of renal failure, the extent to which the drug is normally 
excreted by the kidney, the potential toxicity of the drug if elevated levels 
are inadvertently reached and clinical observations that suggest drug toxicity 
(Vaughaw, 1981). 
2.4. Dialysis: 
Dialysis is a treatment for people whose kidneys have ceased to work 
or whose function has dramatically declined. The patient's blood is cleansed 
through a filter to remove toxins that normally functioning kidneys would do 
on their own. It also removes excess fluid that build up in a renal failure 
patient (Wilson and Wain, 1999). 
Dialysis serves two functions. It cleans the blood of impurities and 
removes excess fluid. If blood is full of these toxins, patients will feel sick, 
and eventually they will harm the whole body. Its fluid bills up too much in 
the body, it can fill the lungs and put too much pressure on the heart. The 
patient may become short of breath or have chest pains. Eventually, death 
will come if left untreated. When a patient is setup for dialysis when he/she 
is given what's called estimated dry weight, this is the weight they are 
supposed to be kept at. Whatever they gain on pounds between treatments is 
taken off at the next treatment. Rapid accumulating weight is caused by 
fluid. Therefore whatever they have gained needs to be removed. If patients 
gain real weight they will have problems, and their weight can be adjusted to 
fix the problem. 
2.4.1 Principle of dialysis: 
Dialysis in chemistry is defined as the transfer of dissolved solids 
(solute) across a semi permeable membrane, which permits or hinders 
diffusion of molecules according to their size. It is frequently used to 
separate different components of a solution. For example, in artificial f1 
kidney machine haemodialysis is used to purify the blood of persons whose 
kidneys have ceased to function. In the machine, blood is 
circulated on one side of a semi permeable membrane, while dialysis fluid-
containing substance necessary to the body and closely matching the 
chemical composition of the blood-is circulated on the other side. Metabolic 
waste products, such as urea, diffuse through the membrane into the dialysis 
fluid and are discarded while the diffusion of substances necessary to the 
body is prevented. 
The principal problems that lead to consideration of dialysis and 
transplantation are growth arrest, severe renal osteodystrophy, 
cardiovascular, circulatory, fluid and acid-base disturbances, malnutrition 
and inadequate caloric intake and inability to carry out normal activities that 
are essential for emotional well-being (Vaughaw, 1981). 
2.4.2 Types of dialysis: 
2.4.2.1. Haemodialysis: 
Haemodialysis employs the process of diffusion across a semi 
permeable membrane (cellulose acetate, cupraphane, polyacrilonitrile, 
polymethylene-acrylate, polysulfonel) to remove unwanted substances from 
the blood while adding desirable components. A constant flow of blood on 
one side of the membrane and a cleaning solution on the other allows 
removal of the waste products in a fashion grossly similar to that of 
glomerular filtration. Haemodialysis equipments consist of three 
components: the blood delivery system, the composition and delivery system 
of the dialysate, and the dialyzer itself. 
Most patients require between nine and twelve hours of dialysis per 
week, equally divided into several sessions. The time depends upon body 
size, residual renal function, dietary intake, complicating illnesses, the 
degree of anabolism or catabolism. The time frequency of treatments, type 
and size of dialyzer, and dialysate composition blood, or dialysate flow may 
all be altered to accomplish specific needs. 
2.4.2.2. Peritoneal dialysis: 
Peritoneal dialysis like haemodialysis may be performed in various 
settings and with a number of different techniques. 
Advantages of haemodialysis are the relatively short treatments time 
and minimal interruption of life-style between treatments. It is more efficient 
than peritoneal dialysis, allowing rapid changes in abnormal serum values 
(Wilson and Wain, 1999). 
2.5. Lipids: 
The lipids are a heterogenous group of compounds related more by 
their physical rather than by their chemical properties. They have the 
common property of being relatively insoluble in water and soluble in non 
polar solvents such as ether, chloroform, and benzene (Murray et al, 1999). 
The major lipids of the body -triglycerides, cholesterol, phospholipids, 
and glycolipids- play a variety of biological roles. They serve as a primary 
source of fuel and are important components of cell membranes and many 
cell structures, they provide stability to the cell membrane and allow for 
trans-membrane transport, and are transported through the blood stream in 
the form of lipoproteins. 
2.5.1 Plasma Lipids: 
The four forms of lipids present in the plasma: Fatty acids, 
Triglycerides, Phospholipids and Cholesterol will be reviewed to reveal their 
relation to kidney failure. 
2.5.1.2. Fatty acids: 
Fatty acids (FA) are the major constituents of triglycerides and 
phospholipids. There are short chain (4-6 carbon atoms), medium-chain (8-
12 carbon atoms), and long-chain (>12 carbon atoms) fatty acids. Depending 
on the number of double -bonds in the molecule, the fatty acids may be 
saturated (no double -bonds) mono unsaturated (one double bond), or poly 
unsaturated (two or more double bonds). 
Fatty acids may be esterified with glycerol to form glycerides, or they 
may be free, when they are called free fatty acids (FF A) or non-esterified 
fatty acids (NEF A). In the plasma FF A are carried mainly bound to 
albumin. Free fatty acids are an immediately available energy source and 
provide a significant proportion of the energy requirements of the body. 
2.5.1.3. Trielycerides: 
The triglyceride (TG) molecule comprises one molecule of glycerol 
with three fatty acids molecules attached (usually three different fatty acids 
including both saturated and unsaturated molecules). Triglycerides 
containing saturated fatty acids without bends pack together closely and tend 
to be solids at room temperature. Unsaturated fatty acids do not pack 
together closely and tend to be liquids at room temperature. 
The source of triglycerides in the body can be either exogenous 
(dietary) or endogenous (synthesized in liver and other tissues). Triglyceride 
molecules allow the body to compactly store long carbon chains (fatty acids) 
for energy that can be used during fasting states between meals. The high 
energy triglyceride molecules, which constitute 95% of fats stored in tissues, 
are transported in plasma mostly in the form of large triglyceride-rich 
lipoproteins called chylomicrons and very low density lipoprotein (VLDL). 
When the triglycerides are metabolized, their fatty acids are released to the 
cells and converted into energy. The glycerol of triglycerides is recycled into 
additional triglycerides. Triglycerides also provide insulation to vital organs 
in the form of fat deposits in adipose cells. The break down of triglycerides 
is facilitated by hormone-sensitive lipase, lipoprotein lipase (LPL), 
epinephrine, and cortisol. The LPL molecules are attached to heparan sulfate 
stalks in the capillaries. As the triglyceride-rich lipoproteins (chylomicrons 
and VLDL) are carried through the circulation, the triglycerides are 
hydrolyzed as they come in contact with LPL. 
The supply of free fatty acids available to the cells to be used in the 
tricarboxylic acid cycle for energy production depends on LPL interaction 
with chylomicrons and VLDL. Hormone-sensitive lipase acts inside adipose 
(fat) cells to release free fatty acids from triglyceride stores for energy when 
dietary sources are unavailable or are insufficient for the body's energy 
needs. Epinephrine and cortisol promote triglyceride breakdown when the 
cells need energy and glucose stores have been depleted. 
2.5.1.4. Cholesterol: 
Cholesterol is an unsaturated steroid alcohol of high molecular 
weight, consisting of a perhydrocyclopentanthroline ring and a side chain of 
eight carbon atoms. In its esterified form, it contains one fatty acids 
molecule. Cholesterol is found almost exclusively in animals. Virtually cells 
and body fluids contain some cholesterol. Cholesterol is used for the 
manufacture and repair of cell membranes, for synthesis of bile acids and 
vitamin D and is the precursor of five major classes of steroid hormones: 
progestin, glucocorticoids, mineralo-corticoids, androgens, and estrogens. 
As with triglycerides, there are both exogenous (dietary) and 
endogenous (primarily hepatic) sources of cholesterol. Diet contributes 100 
mg to 700 mg cholesterol per day (<300 mg / day is recommended for most 
adults). In the body, about 70% of cholesterol is located in stationary pools 
in the skin, adipose tissue, and muscle cells; the remaining 30% or so forms 
a mobile pool that is transported in the form of lipoproteins and circulates 
through the liver. In the blood circulation, two thirds of the cholesterol is 
esterified, and one third is in free form. 
2.5.1.5. Phospholipids: 
Phospholipids, glycolipids, and cholesterol are the three major types 
of membrane lipids. Phospholipids are amphipathic, which means that they 
contain polar hydrophilic (water-loving) head groups and non-polar 
hydrophobic (water-hating) fatty acids side chains. With hydrophilic and 
hydrophobic groups, they act as detergents and are particularly suited to 
serve as major constituents of biological interfaces, such as cell membranes 
and the outer shells of lipoprotein particles. Most phospholipids are formed 
by the conjugation of two fatty acids and a phosphorylated glycerol (Bishop, 
1995). 
 
 
2.5.1.6. Lipoproteins: 
Plasma lipids are derived from food (exogenous) or are synthesized in 
the body (endogenous). They are relatively insoluble in water and are carried 
in body fluids as soluble protein complexes known as Lipoproteins, a core 
insoluble (non-polar) cholesterol esters and triglycerides is surrounded by 
proteins, phospholipids and free cholesterol with their water-soluble (polar) 
groups facing outwards. 
Lipoproteins are classified by their density, which in turn reflects their 
size. The more lipids a complex contains, the larger it is and the lower is its 
density. There are four main classes; triglyceride-rich complexes are two 
they are large, chylomicrons, which transport exogenous lipids from the 
intestine to all cells, VLDL (Very Low Density Lipoprotein), which 
transport endogenous lipids from the liver to cells. 
Because of their large size these complexes reflect light, and plasma 
with increased levels appears turbid or milky (lipaemia). The two smaller 
lipoproteins contain mostly cholesterol, LDL (low Density Lipoprotein), 
which are formed from VLDL and transport cholesterol to cells. High 
Density Lipoproteins (HDL) are involved in the transport of cholesterol 
from the cells to the liver. These small Lipoproteins do not scatter light and 
even very high levels in plasma do not produce lipaemia. A fifth class, 
Intermediate Density Lipoprotein (IDL) is usually a transient intermediate 
lipoprotein formed during the conversion of VLDL to LDL: it contains both 
cholesterol and endogenous triglycerides; IDL is undetectable in normal 
plasma. 
2.5.2 Disorders of lipid metabolism: 
Most common disorders of lipid metabolism are associated with 
hyperlipidaemia. Very rare inherited disorders may be associated with 
accumulation of lipid in tissues and not in plasma. Therefore lipid disorder is 
considered to be of three categories: predominant hyperchlosterolaemia, 
predominant hypertriglyceridaemia and mixed hyperlipidaemia. 
a- Predominant hypercholesterolaemia : 
Plasma cholesterol at birth (cord blood) is usually below 2.5 mmoL/L 
(about 100 mg/dL). Levels increase slowly, mostly during the first year of 
life, but don't usually exceed 40 mmoL/L (about 160mg/dL) in children. It is 
likely that the progressive rise in plasma cholesterol reflects decreasing 
concentration of LDL receptors in the liver. It has been shown that the risk 
of cardiovascular disease increases as plasma cholesterol levels rise above 
5.5 mmoL/litre (about 215 mg/dL). 
b- Mixed hyperlipidaemia : 
Raised plasma levels of both cholesterol and triglycerides are most 
common in patients with poorly controlled diabetes mellitus or sever 
hypothyroid or nephrotic syndrome. The commonest primary cause is 
familial combined hyperlipidaemia with elevated LDL and VLDL. Less 
commonly, increased plasma cholesterol and triglyceride may be equal 
amount of those lipids (Zilva et aI, 1995 ; Bishop, 1995). 
c- Predominant hypertriglyceridaemia: 
Hypertriglyceridaemia (hTG) is a common disorder in the United 
States. It is exacerbated by uncontrolled diabetes mellitus, obesity, and 
sedentary habits, all of which are more prevalent in industrialized societies 
than in developing nations. Hypertriglyceridaemia (hTG) is a risk factor for 
coronary disease. 
Two rare genetic causes of hTG (lipoprotein lipase [LPL] deficiency 
and apo lipoprotein [apo] C-ll deficiency) lead to triglyceride (TG) 
elevations that are astonishingly high. Hypertiglyceridemia can be 
categorized by the Fredrichson classification (analysis of lipids by beta - 
quantification -ultra centrifugation followed by electrophoresis). In this 
classification, all but 1 of the hyperlipidemias, type 11 a, is characterized by 
elevated TGs - types 1, 11 b, III, IV, and V. 
Triglycerides are synthesized in the liver and intestine and packaged 
into lipoproteins. Chylomicrons are synthesized in the intestine, and VLDLs 
are synthesized in the liver. These lipoproteins transport TGs and cholesterol 
throughout the circulation. TGs comprise approximately 50 % of the dry 
weight of VLDLs and chylomicrons respectively. and are present in LDL 
and high - density lipoprotein (HDL) in much smaller quantities. Any 
disturbance that causes increased synthesis of chylomicrons and/or VLDLs 
or decreased metabolic break down will cause elevations in TG levels. That 
disturbance may be as common as dietary indiscretion or as unusual as a 
genetic mutation of an enzyme in the lipid metabolism pathway. 
In the US: If hTG is defined as fasting TGs greater than 2000 mg/dL 
the prevalence in the United States is approximately 10% in men older than 
30 years and women older than 55 years. Prevalence of sever hTG, defined 
as TGs greater than 2000 mg/dL is estimated to be 1-8 cases per 10,000 
adult whites, with a higher prevalence in patients with diabetes or 
alcoholism. 
Hypertriglyceridemia is correlated with an increased risk of 
cardiovascular disease (CVD) particularly in the setting of low HDL 
cholesterol (HDL-C) levels and/or elevated LDL cholesterol (LDL-C) levels. 
Extreme elevations of TGs, usually greater than 1000 mg/dL, may 
cause acute pancreatitis. A less severe, and often unrecognized, condition is 
the chylomicronemia syndrome, which usually is caused by TG levels 
greater than 1000 mg/dL. In the prospective cardiovascular Munster study, a 
large observational study, mild hTGs (TGs > 200 mg/dL) was more 
prevalent in men (18.6 %) than in women (4.2 %). TGs increase gradually in 
men until about age 50 years and then decline slightly. In women they 
continue to increase with age. TGs are lower in African Americans 
compared with whites. Hypertriglyceridemia usually is asymptomatic until 
TGs are greater than 1000 -2000 mg/dL. TG levels often exceed 5000 mg/dL 
at the onset of pancreatits. Sever hTG may cause eruptive xanthomas, which 
is a benign condition. When TGs are acutely and massively elevated, 
physical findings may be absent except on funduscopic examination. 
Hypertriglyceridemia has many causes including familial and genetic 
syndromes, metabolic disease, and drugs. Other causes of hTG are: 
Alcohol, high carbohydrate diets (>60 % of calorie intake), acute 
pancreatitis and pregnancy. 
The latest Adult Treatment Panel guidelines (A TP III) (Talavera, 
2004) have        reclassified serum triglycerides levels as follows: 
 
 
A few very rare disorders will be briefly mentioned as they illustrate 
aspects of the normal pathway. They are associated with reduced plasma 
Classification TG level (mg /dL) 
Normal TG level <150 
Borderline-high TG level 150-199 
High TG level 200-499 
Very high TG level >500 
level and tissue lipid accumulation despite low plasma levels (Citkowitz, 
2004). 
d- Lipid Metabolism in CRF: 
Chronic renal failure patients suffer from a secondary form of 
complex dyslipidemia, similar to the so-called atherogenic dyslipidemia in 
insulin resistant patients or to diabetic dyslipidemia. The most important 
abnormalities are an increase in the serum level of triglyceride (elevated 
VLDL -remnants / IDL), small LDL particles and low HDL cholesterol. The 
highly atherogenic LDL sub class, namely LDL.6 or small dense  IA LDL, 
accumulates in hypertriglyceridemic diabetic haemodialysis patients. All 
these lipoprotein particles contain apo B, much of this complex disorder can 
be summarized as an elevation of triglyceride-rich apo B containing 
complex lipoprotein particles. Growing evidence suggests that all of the 
components of this type of dyslipidemia are independently atherogenic. 
Further disturbances exist in the dynamics of cholesterol exchange between 
the various lipoprotein particles and in transport from cells to catabolic sites. 
The European Joint Task Force and the US National cholesterol Education 
Program expert panel have issued guidelines for the general population to 
lower the cardiovascular risk in hyper-and dyslipidemias. There is 
preliminary consensus that these guidelines should be applied to dialysis 
patients. However, the genesis of arteriosclerosis in the dialysis population 
may be different and real benefit from lipid lowering has not yet been 
demonstrated in this population (Wanner, 2001). 
The study demonstrates a correlation between abnormalities of lipid 
metabolism and the degrees of kidney insufficiency, and a correlation within 
certain kinds of lipid criteria in patients with different degree of renal 
damage. The results suggest the existence of multi-correlations in vivo in 
catabolism and metabolism of lipid, lipoprotein, apo lipoprotein, and protein 
in the patients. The exact mechanism responsible for the association and 
correlation remains to be clarified (Yang et aI, 1999). 
However, recent studies have postulated that glomerulosclerosis is 
induced by hyperlipidemia and is in common with atherosclerosis. This 
involvement is found in the progressive renal disorders, e.g focal 
glomerularsclerosis, diabetic nephropathy and glycogen storage disease. 
Interaction between macrophages and mesangial cells may play an important 
role in such condition. On the other hand, discovery of new hereditary 
metabolic disorders, such as type III hyper lipoproteinemia and lipoprotein 
glomerulopathy, shows that apo lipoprotein (apo) E abnormalities are 
responsible for the glomerular lesions (Saito, 1997). 
These results suggest a limited role for dyslipidaemia in the 
progression of chronic renal disease to dialysis in CRF patients, in contrast 
with the powerful influence of proteinuria, baseline, creatinine clearance and 
nephropathy type in predicting this progression (Massy et aI, 1999). 
Lipid reduction may preserve glomerular filtration rate and may 
decrease protein in patients with renal disease (Fried et aI, 2001). 
Abnormalities in circulating lipoproteins are common in patients with 
renal disease. The pathogenesis and specific type of lipid abnormality vary 
according to the type of renal disease and the modality of treatment. The 
pattern of lipid abnormalities can be quite different in nephronic syndrome, 
in renal insufficiency without nephrotic syndrome, with haemodialysis of 
peritoneal dialysis, and after kidney transplantation. Consequently, the 
management of lipid abnormalities in each of these clinical setting is often 
different (Mitch et al 1998). 
The most characteristic feature of the CRD associated dylipidaemia is 
the accumulation of apo lipoprotein-B- containing triglyceride-rich 
lipoprotein particles in the very low density (VLDL) and intermediate 
density range (IDL). This results in increased serum triglycerides in 
conjugation with low levels of high density lipoprotein (HDL) cholesterol 
(Wanner, 2000). 
Chronic renal failure is characterized by specific alterations of the  
lipoprotein metabolism. It has been suggested that renal dyslipoproteinemia 
contributes to the progression of renal dysfunction. In particular, elevated 
levels of intact or partially metabolized triglyceride rich apo B- containing 
lipoproteins of intermediate- and low- density ranges seem to promote the 
progression of human renal insufficiency (Samuelsson et aI, 1998).  
The long-term haemodialysis does not act on lipid anomalies 
following CRF. Alterations in HDL composition contribute to the reduced 
efficacy of reverse cholesterol transport, which is a risk factor for 
cardiovascular disease (Mekki et aI, 2002). 
Oxidative modification of both LDL and HDL occur in patients with 
advanced CRF resulting in small lipoproteins. Increased production of ox 
LDL and ox HDL is the main cause of lipid metabolic abnonnality in CRF 
patients (Tsumura et aI, 2001). 
The highly atherogenic LDL subclass, namely LDL-6 or small dense 
LDL, accumulates preferentially in hypertriglyceridemic diabetic patients 
with nephropathy or on haemodialysis treatment. All these lipoprotein 
particles contain apo lipoprotein B, thus the complex disorder can be 
summarized as an elevation of triglyceride-rich apo lipoprotein B- 
containing complex lipoprotein particles. Growing evidence suggests that all 
of the components of this type of dyslipidemia are independently 
atherogenic (Wanner, 2001). 
A study by Liang and Vaziri (2002), found marked down regulation of 
hepatic lecithin cholesterol acyl transferase, or LCA T, expression, which 
can account for impaired HDL maturation and depressed HDL cholesterol 
concentration in chronic renal failure. Thus CRF results in significant up 
regulation of hepatic ACAT-2 (but not ACAT-l) expressIOn and ACA T 
activity, which may, in part contribute to the associated lipid disorders 
(Liang and Vaziri, 2002). 
The lipid abnonnalities are characterized by an increase in plasma 
triglycerides and cholesterol in nearly all lipoproteins (VLDL, IDL, LDL), 
where as HDL cholesterol is reduced, dyslipidemia becomes more 
pronounced as renal failure advances and become aggravated when patients 
start renal replacement therapy. The increase in apo B 1 00 is mostly marked 
in the VLDL fraction and to a minor extent for IDL and LDL. 
e- Proposed mechanisms for hypertriglyceridemia in CRF: 
An impaired triglyceride removal is often proposed as the cause of 
hypertriglyceridemia in pre-dialysis patients as well as in patients on 
dialysis. Additionally, two studies suggest the involvement of an increase in 
triglyceride synthesis rate or VLDL apo B 100 overproduction. It is 
reasonable to believe that disturbances are present in both VLDL catabolism 
and synthesis. 
Overproduction of VLDL-l apoB 1 00 and VLDL-2 apoB 100 
observed in patients with CRF is most likely the result of different metabolic 
routes. It has been suggested that increased free fatty acids (FFA) 
availability from peripheral tissues (muscle and adipose tissue) could be of 
major importance in determining hypertriglyceridemia. The increased FFA 
availability could subsequently stimulate the production of apo BI00-
containing lipoproteins (Figure.2a and 2b). Alternatively, fatty acids for 
VLDL apoB secretion could also be derived from de novo lipogenesis. 
A possible disturbance in both lipoprotein lipase and hepatic lipase, 
accompanied by an increase in apo C 111 in VLDL, result in prolonged half 
life of VLDL particles, which may explain the observed 
hypertriglyceridemia in these patients (Berthil et aI, 2003). 
 
 LDL levels are usually normal or low in patients on haemodialysis. 
The same apo lipoprotein abnormalities of predialysis renal insufficiency are 
common in patients treated with haemodialysis. There is no doubt that the 
morbidity and mortality from atherosclerosis are very high in haemodialysis 
patients (Mitch et al, 1998). 
 Plasma triglycerides are increased in the majority of patients with 
advanced renal failure but cholesterol is not. HDL cholesterol is reduced 
while LDL and VLDL cholesterol is increased. Lecithin Cholesterol acyl 
transferase (LCA T), an enzyme necessary for HDL maturation, is reduced 
in chronic renal failure (CRF). Lipoprotein catabolic rate is reduced but the 
cause of hyperlipidemia is multi - factorial. Hyperlipidemia is not corrected 
by dialysis (Kaysen, 1994). 
The study of (Shah, 1994) suggests the following: 
1) Significant hypertriglyceridemia does develop in a majority of CRF 
patients. The abnormality probably improves with dialysis of CRF 
treatment and renal transplantation 
2) A lower apoAl, /apoB ratio in CRF patients may account for higher 
risk of atherosclerosis (Shah, 1994). 
Lipid abnormalities are common in patients with renal disease, 
probably contributing to the high incidence of cardiovascular diseases. 
Gomez-Dumm et al (2001) determined the plasma and erythrocyte lipid 
profile in patients with chronic renal failure (CRF) along 30 months under 
haemodialysis. Triglycerides levels were found to increase in the plasma and 
in erythrocyte membranes of CRF patients compared to healthy subjects. 
Plasma polyunsaturated fatty acids decreased whereas palmitic and mono 
unsaturated fatty acids increased in CRF patients. The lipid composition 
abnormalities persisted after 18 months and they become more notrious after 
30 months. Neither plasma nor the erythrocyte membrane lipid pattern 
changed in CRF patients during the dialysis session, regardless of the 
dialysis membrane used. The study I), concluded that CRF patients under 
regular haemodialysis evidence a gradual deterioration in the fatty acid and 
triglycerides abnormalities, a finding that might be relevant to the risk of 
cardiovascular disease in this setting (Gomez-Dumm et aI, 2001). 
Fasting hypertriglyceridemia is a well known abnormality in CRF. 
The majority of Patients of Western Population belong to type IV pattern of 
hyperlipoproteinemia. Bagdade et al (1968) originally found both increased 
synthesis and decreased clearance of very low density lipoprotein (VLDL), 
in uremic patients as a cause of hypertriglyceridemia (Ravichandran et aI, 
1983). 
Other than the recognized atherogenic lipoprotein levels, little is 
known about overall cholesterol metabolism in patients on chronic 
haemodialysis (HD) and the best therapeutic intervention is still being 
debated. Reduced HDL cholesterol and reduced bile acid synthesis 
contributes to atherosclerosis pathogenesis in dialysis patients, whereas 
intestinal cholesterol absorption and hepatic cholesterol synthesis does not 
seem dominant in this process at this stage of disease (Igel-Korcagova et aI, 
2003). 
The incidence of CVD in CRF accounts for 40% to 500/0 of deaths 
among patients on renal replacement therapy. Risk factors for CVD can be 
divided in traditional and uremia-related factor. It is important to note that 
most of these risk factors are associated with endothelial dysfunction, which 
is almost invariably present in chronic renal failure (CRF) and may be the 
common link between risk factors and CVD (Berthil et aI, 2003). 
In the non dialysis population, there is overwhelming evidence that 
treatment of dyslipidemia can significantly improve cardiovascular 
outcomes. Accumulating data indicate that dialysis patients have atherogenic 
lipid abnormalities. Although LDL cholesterol (LDL-C) levels in patients 
who undergo haemodialysis are normal or near normal, increased oxidized 
LDL-C, triglycerides, and lipoprotein (a) [LP (a)]; decreased HDL 
cholesterol (HDL-C); and triglyceride-rich VLDL have been noted 
(Prichard, 2003). 
 
 
 
 
CHAPTER THREE 
 
MATERIALS AND METHODS 
 
 
3.1. Materials: 
 
3.1.1. Study subjects: 
 
The study included 46 patients who were undergoing maintenance 
haemodialysis for periods between 6 months and 60 months. The selected 
patients comprised 35 males and 11 females and marked as  group I. 
Another 20 healthy volunteer persons were also included in this study as a 
control comprising 11 males and 9 females, marked as group II. 
All patients with renal disease or chronic renal failure who 
participated in this study were briefed with the purpose of this research.all 
patients expressed their approval. Regardless of the duration of their illness, 
both the study groups, patients and control, were matched for age and sex. 
All patients participated in this study were seen at Khartoum Kidney 
Dialysis Unit, during the period March 2004 to April 2004. All clinical 
examination assessments and disease complications were conducted by 
medical doctors at the unit. The etiology of chronic renal failure (CRF) was 
hypertension diabetes mellitus and kidney disease. 
 
 3.1.2. Treatments: 
 
In the first group 46 patients were subjected to haemodialysis (the 
haemodialysis was carried for 4 hours) according to the medical condition of 
the patients assessed by doctors. 
The blood samples of all the patients were collected for lipid profile 
analysis after an over- night pre-dialysis fast.Group II (control) were used 
for lipid estimation comparison, in which samples of blood were taken after 
an overnight fast.  
3.2. Methods: 
 
The clinical assessments and chemical investigation were carried out 
for all patients under the study at the onset. The vitalab analysis, a universal 
system, where all liquid handing and measurements took place and was used 
for the quantitative determination of the serum triglyceride, cholesterol, urea 
and creatinine concentration with the selection analysis system. However, 
the electrolytes K + and Na+ were measured using a flame photometer 
3.2.1. Blood collection and handling:: 
 
Five ml of venous blood were taken from pre-haemoliglysis patients 
using a fistula. The venous blood was taken from control subjects as well. 
All blood samples taken were drawn into plane containers, centrifuged and 
the serum was then obtained. 
The blood samples of the two groups were transferred individually to 
the vitalab analysis for quantitative determination. The samples were 
prepared for vitalab analysis as follows: 
Each sample was given a reference number. Two ml of the samples 
Were pippited  in the tubes of vitalab analysis. Then the calibrator tube was 
prepared by mixing two reagents together and then 2 ml was taken. The 
blank was prepared by taking 2 ml of distilled water. 
The 46 samples were run into two patches and the samples of controls 
in one patch. The patch was taken 40 minutes and then the system 
automatically provided a printout of results and evaluations. 
The electrolytes K + and Na+ were measured by a flame photometer 
as follows: 
Five ml of distilled water was prepared in a tube as blank and another 
5ml in a different tube as a standard. An aliquat of 0.05 ml of serum from 
each sample was added to 5 ml of distilled water in a separate tube. Then all 
the samples were read against the flame photometer and the results were 
taken. The group I samples were done in four patches and the samples of 
controls (group II) in two patches. 
3.2.2. Estimation of serum triglycerides: 
3.2.2.1. Principle: 
 
Enzymatic determination of triglycerides was carried according to the 
following reactions 
TG + H2O    Lipoprotein lipase    Glycerol + Fatty acid. 
Glycorol + ATP    Glycerol Kinase             Glycerol. 3. Phosphate + ADP. 
Glycerol. 3. Phosphate + O2          GPO      Dihydroxyacetone Phosphate 
+ H202.                 
H202 +  4.AAP + p. chlorphenol    peroxidase        Red quinoneimine.   
 
4.AAP = 4.amino antipyrine 
GPO = Glycerol -3- Phosphate Oxidase. 
3.2.2.2. Reagent composition: 
 
The reagent was composed of: pipes buffer- pH 7.00 (50 mmol/L), p. 
chlorphenol (5.3 mmol/L), potassium ferrocyanate (10 mmol/L), magnesium 
salt (17 mmol/L), 4.amino antipyrine (0.9 mmol/L), ATP (3.15 mmol/L), 
lipoprotein lipase (> 1800 U/L), glycerol kinase (> 450 U/L), glycerol-3- (P) 
oxidase (>3500 U/L) and peroxidase (>450 U/L). 
The calibrator was ELICAL. 
3.2.2.3. Preparation of working reagents: 
 
Twenty volumes of reagent 1 were mixed with one volume of 
reagent2. 
The mode was end point, the wavelength was 546 nm, the units were 
mg/dL, the decimals were 2, the Rl bottle was 25 mL, its normal volume 
was 300 ml and its rerun volume was 30 mL. The sample normal volume 
was 3.0 ml and the incubation time was 4.5 minutes. 
3.2.2.4. Calculation: 
 
∆ OD sample 
x N 
∆ OD calibrator 
N = calibrator concentration; OD = optical density. 
 
3.2.3. Estimation of serum cholesterol: 
Principle: 
Enzymatic colorimetric determination of total cholesterol was 
performed according to the following reactions: 
Cholesterolester + H2O Cholesterol esterase   cholesterol + fatty acids 
Cholesterol + O2   cholesterol oxidase   4.cholestrene. 3. one + H2O2                                                                 
2H2O2 + phenol + 4-Amino antipyrine    peroxidase          red quinone + 
 4 H2O  
3.2.3.1. Reagent composition: 
 
The reagent was composed of Pipers buffer, pH 6.70 (50 mmol/L), 
phenol (24 mmol /L), sodium cholate (0.5 mmol/L), 4.amino antipyrine (0.5 
mmol/L), cholesterol esterase (> 180 U/L), cholesterol oxidase (> 200 U/L) 
and peroxidase (> 1000 U/L).The calibrator was ELICAL. 
3.2.3.2. Preparation of working reagents:  
 
The reagent (2) was dissolved in reagent (1). The mode was end point, 
the wavelength was 505 nm and the units were mg/dL. R1 bottle was 25 ml, 
its normal volume was 300 ml and its rerun volume was 301 ml. The sample 
normal volume was 3.0 ml and its rerun volume was 2.0 ml. The working 
temperature was 37°C and the incubation time was 4.5 minutes. 
 
3.2.3.3. Calculation: 
 
∆ OD sample 
x N 
∆ OD calibrator 
 
N = calibrator concentration;     OD = optical density. 
 
3.2.4. Estimation of electrolytes: 
Electrolytes moved either to the cathode (-ve charge) or to the anode 
(+ve charge) when supplied to electrical electrolyte field. The most common 
electrolyte K+ and Na+ were used, they were measured by flame 
photometer. (Na+, is a major extra cellular cation while K+ is a major 
intracellular cation). 
The selected filter for K+ was (766 - 770 nm), the electrolyte button 
was switched on, gas was supplied on maximum, the flame was 
ignited and distilled water was sucked with a pump which was used to : 
1- Adjust zero as blank. 
2- Wash the machine 
The flame was adjusted until a blue concentrated shape was formed, 
the standard was sucked low at the beginning and then high. Then each 
specimen was sucked and read. After that distilled water was sucked for 
zeroing the machine again. 
K+ Concentration of the serum samples of group I and II was 
calculated as: Test / Standard x concentration of Standard. 
Preparation of Na + and K+ standard reagents: 
 
The standard reagent was prepared using either Na+ chloride or K+ 
chloride. 
The standard reagent of K+ was prepared by dissolving K+ CL (Mwt 
= 74.5) in 1 Litter. 
3.2.5. Estimation of urea: 
Principle: 
Enzymatic determination was done according to the following 
reactions: 
Urea + H2O   urease        2NH3 + CO2 
 
2NH4+ + 2α - Keto glutarate + 2 NADH   GL/DH    2LGlutamate + 2NAD+ + 
2H2O 
GL/DH = Glutamate dehyrogenase. 
 
3.2.5.1. Reagent composition: 
Reagent (1) was composed of tris buffer, pH 7.60 (100 mmol/L), ADP 
(0.7 mmol/L), α. ketoglatarate (9 mmol/L), urease (> 6500 U/L) and GL/DH 
(> 1 100 U/L). Reagent (2) was composed of NADH (320 mmol/L) , and the 
calibrator was ELICAL. 
3.2.5.2. Procedure: 
The mode was two points, the wavelength was 340 nm, the units were 
mg/dL and the working temperature was 37°C. 
3.2.5.3. Calculation: 
∆ OD sample 
x N 
∆ OD calibrator 
N = calibrator concentration; OD = optical density. 
3.2.6. Estimation of serum creatinine: 
Principle: 
The rate of formation of a colour complex between creatinine and alkaline 
picrate was measured. The effect of interfering substances were reduced 
using the kinetic procedure. 
 
3.2.6.1. Reagent composition: 
Reagent (1) was composed of picric acid (8.73 mmoI/L), reagent (2) 
was composed of sodium hydroxide (300 mmol/L) and disodium phosphate 
(25 mmol/L). The calibrator was ELICAL. 
3.2.6.2. Preparation of working reagent: 
One volume of reagent (1) was mixed with one volume of reagent (2). 
3.2.6.3. Procedure: 
The mode was two point, the wave length was 505 nm, the units were 
mg/dL, the decimal was 1, the working temperature was 37°C and the 
sample volume was 14 m1. 
3.2.6.4. Calculation: 
∆ OD sample 
x N 
∆ OD calibrator 
N = calibrator concentration; OD = optical density. 
 
CHAPTER FOUR 
RESULTS 
Table (I) shows the mean and standard deviation for serum urea, 
creatinine,  
K +, Na, cholesterol and triglyceride levels of fourty six patients with 
chronic renal failure who were on maintenance haemodialysis for at least six 
months. The minimum and maximum values were given for each parameter 
for the selected patients who comprised 35 males and 11 females. Table (II) 
and figures (7a) and (7b) show the serum cholesterol (mg/dL) and serum 
triglyceride (rilg/dL) levels in it haemodialysis patients compared to serum 
derived from control samples of twenty healthy persons comprising 11 
males and 9 females. 
It can clearly be seen that there is a significant difference between the 
serum cholesterol and serum triglyceride levels between patients and control 
subjects as presented in the mentioned tables and figures. 
Table (III) represents the cholesterol levels of 10 of the CRF patients 
where the mean and standard deviation were 131.5 + 29.83. However, 
cholesterol level of the remaining 36 patients was 131.5 + 39.40. The mean 
and standard deviation of triglyceride levels of the 10 CRF patients was 
found to be 156.6 + 71.07, however, 36 patients gave values of 164.25 + 
59.20. 
 
Figures (3a) and (3b) show the percentage of serum cholesterol levels 
of subjects with familial post history where results indicate equal levels of 
cholesterol in both healthy and affected subjects. 
Table (IV) indicates that patients under hamodialysis have a family 
history disease in which the cholesterol 10 CRF patients mean and std. 
Deviation was being 131.09 + 35.20 and 36 non renal patients was 
131.88 + 39.73 respectively while triglyceride 10 CRF patients mean and 
std. Deviation was being 154.81+ 66.29 and 36 non renal patient was being 
170.29 + 51.46  and the figures (4 - a), (4 - b) show the percentage. 
Table (V) and figure (5 - a) and figure (5 - b) represent the mean and 
std. Deviation of age of serum cholesterol and serum triglyceride of CRF 
patients subjected to haemodialysis. 
Tab Ie (VI) and figure (6 - a) and figure (6 - b) show the mean and std. 
Deviation of serum cholesterol and serum triglyceride values which is not 
significant in both sexes. But the values of triglyceride female were slightly 
decreased than male. 
Table (VII) shows the sources of variation by using ANOVA test to 
comprise between the two groups. 
 
 
 
 Table (I): 
 
The minimum and maximum levels of serum urea (mg/dL), creatinine 
(mg/dL), K+ (U/L), Na (U/L), cholesterol (mg/dL) and triglyceride (mg/dL) 
in patients with chronic renal failure (CRF). Average mean and Standard 
Deviation were calculated. 
 
Variable Urea 
mg/dl 
Creatinine
Mg/dl 
K+ 
U/L 
Na 
U/L 
Cholesterol 
Mg/dl 
TG 
Mg/dl 
N 
 
 
Mean 
 
Std. 
Deviation 
 
Minimum 
 
Maximum 
46 
0 
 
147.54 
 
39.10 
 
 
63.00 
 
254.00 
46 
0 
 
9.45 
 
2.64 
 
 
3.50 
 
14.00 
46 
0 
 
5.10 
 
1.27 
 
 
2.40 
 
8.50 
46 
0 
 
137.65 
 
12.25 
 
 
105.00 
 
169.00 
46 
0 
 
131.50 
 
37.22 
 
 
81.00 
 
260.00 
46 
0 
 
162.59 
 
61.20 
 
 
56.00 
 
322.00 
 
N = number of cases. 
 
 
 
Table (II): 
Comparison between serum cholesterol (mg/dL) and triglyceride (mg/dL) 
means in patients with chronic renal failure (CRF) and the control group. 
The table shows the mean + standard deviation and probability (P). 
N = number of cases. 
 
      Variable Patients 
(N=46) 
Control 
(N=20) 
P 
 
S. cholesterol 
 
131.5 + 37.22 
 
156.2 + 42.69 
 
< 0.05 
 
S. triglycerides 
 
162.59 + 61.20 
 
90.8 + 21.40 
 
< 0.05 
 
 
(t) Test was used for the comparison. 
 
 
Table (III): 
Shows comparison between serum cholesterol ( mg/dL) and triglyceride 
(mg/dL) mean + standard deviation, of post history in patients with chronic 
renal failure under haemodialysis. 
 
Variable Post history N Mean + Std.D 
 
Cholesterol 
 
 
Renal 
Non renal 
 
10 
36 
 
131.5 + 29.83 
131.5 + 39.40 
 
 
Triglyceride 
 
 
Renal 
Non renal 
 
10 
36 
 
 
156.6 + 71.07 
164.25 + 59.20 
 
 
 (t) Test was used for the comparison. 
 
 
 
Table (IV): 
Shows comparison between serum cholesterol (mg/dL) and triglyceride 
(mg/dL) mean + standard deviation, in patients with family history of 
chronic renal failure under haemodialysis. 
 
Variable Family N Mean + Std.D 
 
S.cholesterol 
 
Renal 
Non renal 
 
10 
36 
 
131.09 + 35.20 
131.88 + 39.73 
 
S.triglyceride 
 
Renal 
Non renal 
 
10 
36 
 
154.18 + 66.29 
170.291 + 56.46 
 
 
Std. D= standard deviation 
(t) Test was used for the comparison. 
 
 
Table (V): 
 
Shows comparison between serum cholesterol means (mg/dL) and 
triglyceride means (mg/dL) in different age groups. The table gives the mean 
0} standard deviation. 
N = number of cases. 
S= Serum 
 
Age 
Group 
N S.cholesterol S. triglyceride 
15-27 
 
28-40 
 
41-53 
 
54-66 
 
67-79 
 
80-92 
8 
 
9 
 
15 
 
11 
 
0 
 
3 
114.13+t 19.50 
 
112.89 + 21.60 
 
145.73 +40.95 
 
138.64 +42.84 
 
0 
 
136.33 +49.50 
152.75 + 50.56 
 
142.33 + 59.36 
 
180.93 +66.60 
 
161 + 63.21 
 
0 
 
163.670+ 73.79 
 
 
 
(t) Test was used for the comparison 
 
Table (VI): 
 
Shows comparison between serum cholesterol means (mg/dL) and serum 
triglyceride means (mg/dL) in male and female patients with chronic renal 
failure (CRF). The table gives the mean -+ standard deviation. 
N = number of cases. 
S= Serum 
 
Variable Sex Mean + Std.D P 
S.cholesterol           Male 
Female 
130.11 + 0.38 
135.91 +  0.34 
>0.05 
S.triglycerides           Male 
Female 
167.09 + 0.61 
148.27 +  0.60. 
 
>0.05 
 
 
(t) Test was used for the comparison. 
 
Table (VII): 
 
Source of variation revealed by using ANOV A test for the two study 
groups. 
 
Variable Source of  
variation 
Sum of 
squares 
Df Mean 
square 
F Sig. 
 
Cholesterol Between 
Groups 
 
Within 
Groups 
 
Total 
8504.29  
 
 
96960.70 
 
 
105464.99
1 
 
 
64 
 
 
65 
8504.29 
 
 
1515.01 
5.61 .02 
Triglyceride Between 
Groups 
 
Within 
Groups 
 
Total 
71834.81 
 
 
177256.35
 
 
249091.17
1 
 
 
64 
 
 
65 
71834.81 
 
 
2769.63 
25.94   .00 
 
 1
2
 
 
Figure (3 a): Comparison between percentages (%) of mean serum 
cholesterol level according to post history in patients with chronic renal 
failure (CRF) under haemodialysis. 
Renal = patients with post history of CRF; Non renal = patients with no post 
history of CRF  
50% 
Renal 
50% 
Non renal 
1
2
 
 
 
 
Figure (3b): Comparison between percentage (%) of serum Triglyceride 
means according to post history in patient with chronic renal failure (CRF) 
under haemodialysis. 
Renal = patients with post history of CRF; Non renal = patients with no post 
history of CRF. 
51% 
Non renal 
49% 
Non renal 
 1
2
 
 
 
 
 
Figure (4a): Comparison between percentage (%) of serum Cholesterol 
means according to family history in patients with chronic renal failure 
(CRF) under haemodialysis. 
50% 
Non renal 
50% 
Renal 
1
2
 
 
 
 
Figure (4b): Comparison between percentage (%) of serum Triglyceride 
means according to family history in patients with chronic renal failure 
(CRF) under haemodialysis. 
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Figure: (5a): Comparison between serum Cholesterol means (mg/dl), in 
different age groups of patients with chronic renal failure (CRF). 
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Figure (5b): Comparison between serum Triglyceride means (mg/dL), in 
different age groups of patients with chronic renal failure (CRF). 
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Figure (6a): Serum Cholesterol means (mg/dL). In male and female patients 
with chronic renal failure (CRF). 
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Figure (6b): Serum Triglyceride means (mg/dL) in male and female patients 
with chronic renal failure (CRF). 
 
 
 
        
115
120
125
130
135
140
145
150
155
160
patient control
 
 
 
Figure (7a): Comparison between serum Cholesterol means (mg/dL) in 
patients with chronic renal failure (CRF) and control subjects. 
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Figure (7b): Comparison between serum Triglyceride means (mg/dL) in 
patients with chronic renal failure (CRF) and control subjects. 
 
 
 
 
CHAPTER FIVE 
DISCUSSION 
 
Renal failure has been recognized as a major health problem occurring 
in almost all populations of the world and at a variable prevalence in Sudan, 
it has been estimated from hospital records that the number of chronic renal 
failure (CRF) patients is increasing in all socioeconomic classes and about 
60% of all Sudanese renal failure patients attend renal dialysis centers in the 
central state. 
Recognizing renal failure as an increasing international public health 
problem, international and national efforts have been devoted to assess the 
importance of chronic renal failure (CRF) and implement population based 
measures for prevention and control of the disease. 
In Sudan, there has been an increasing number of the incidence of 
renal disease in the past decade, with a concomitant increase in kidney 
failure patients. 
Hypertriglyceridemia, manifested as turbidity of plasma after an 
overnight fast, has been recognized in patients with uremia over a century. 
However, only recently it has been possible to identify the exact type of lipid 
abnormality and the underlying mechanism. The lipid abnormality could be 
due to increased hepatic synthesis of very low density lipoprotein (VLDL) 
triglycerides and / or defective triglyceride removal. 
Fasting hypertriglyceridemia is a well known abnormality in chronic 
renal failure (CRF) of Western population. The majority of these patients 
belong to Type IV pattern of hyperlipoproteinemia. It is found that both 
increased synthesis and decreased clearance of very low density lipoprotein 
(VLDL), in uremic patients is a cause of hypertriglyceridemia. 
In India, they did not find any lipid abnormality in patients of chronic 
renal failure who were either on regular haemodialysis or being managed 
conservatively. They attributed this to the low calories derived from 
carbohydrates and the high intake of polyunsaturated fatty acids in the diet. 
Most studies have reported reduced high density lipoprotein (HDL) 
levels in patients with chronic renal failure (CRF) and an average normal or 
even subnormal total and low density lipoprotein (LDL) and cholesterol 
levels. 
In this study in Sudan hypertriglyceridemia was observed in (43.5 %) 
of chronic renal failure (CRF) on conservative treatment, but cholesterol was 
observed to be at normal levels in all the patients. 
The exact mechanism by which hyperlipidemia worsens renal disease 
is not known. Hyperlipidemia alone does not appear to cause renal disease, 
although patients with hereditary lipid disorder, such as lecithin- cholesterol 
acyl transferase deficiency, develop proteinuria and renal failure. 
Most of the earlier studies showed that lipids are not predictive for 
cardiovascular disease in dialysis patients. However, this does not mean that 
they are not contributing to the tremendous cardiovascular risk. 
In summary, hypertriglyceridemia is the most common form of lipid 
abnormality seen in patients with chronic renal failure (CRF) and it is one of 
the risk factors for cardiovascular disease (CVD). 
 
CHAPTER SIX 
Conclusions and Recommendations 
6.1. Conclusions: 
The effects of dyslipidemia on the kidney are mainly observed in 
those with other risk factors for renal disease progression such as 
hypertension, diabetes mellitus and proteinuria. 
Since at the moment no direct evidence is present concerning the 
relevance of the different metabolic routes for hypertriglyceridemia in 
chronic renal failure patients, it is still a speculation of which metabolic 
route is of major importance. On the other hand, hypertriglyceridemia may 
be multifactorial. 
Hypertriglyceridemia, one of the risk factors for cardio vascular 
disease (CVD), is observed in patients with chronic renal failure (CRF). 
Because of its direct contact with the circulating blood, the endothelium is 
preferentially subjected to the modulatory effects of these altered 
lipoproteins. 
Optimal treatment of metabolic derangements is essential, since 
hypertriglyceridemia results in endothelial dysfunction and may constitute 
important risk factors for development of atherosclerosis in chronic renal 
failure (CRF) patients. 
 
 
   6.2. Recommendations 
 
On the light of this study and knowledge gained, I would like to 
recommend                                                                                                            
the following: - 
1. Hypertriglyceridemia is the most common form of lipid 
abnormality seen in patients with chronic renal failure (CRF), this 
abnormality seems to improve after initiation of dialysis and after 
renal transplantation, unfortunately, the cost of renal dialysis and 
transplantation are very high, and definitely beyond the financial 
capability of the poor. So it is time for the ministry of health to 
reduce the cost of these types of treatment or to make it free. 
2. Still, dialysis is not a cure, if patient kidneys are temporarily 
damaged, Dialysis can give them a rest and a chance to recover, 
but for chronic end stage renal disease, a kidney transplant is the 
only long-term solution that frees the patient from dialysis. 
3. The leading causes of end stage renal disease are diabetes mellitus 
and hypertension, managing these diseases can go along way 
towards preventing kidney failure and the need for dialysis. 
4. Care must be taken to keep a healthy kidney; this can be done by 
taking balanced diet and drinking enough water to keep kidneys 
working fine. 
5. The real kidney killers are the drugs, some antibiotics, anesthesia, 
medication and antipsychatric drugs that may damage kidneys; 
avoidance of using these drugs is advisable. 
6. Avoiding use or contacting some chemicals which damage kidneys 
such as chemical solutions, wood alcohol, toluene, carbon tetra 
chlorides and ethylene glycol, care must be taken when handling 
these chemicals. 
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APPENDIX 
QUESTIONNAIRE 
 
On chronic renal failure in Sudanese patients under dialysis for :- 
The degree of M. Sc qualifying. 
Supervisor: 
Dr/Sumaia Abu Kashawa. 
Patient NO: -------------------------------------------------------- 
(1) General Information: 
1- Name: ------------------------------------------------ 
2- Age: ------------------------------------------------ 
3 - Sex: ------------------------------------------------ 
4- Occupation: ----------------------------------------- 
5 - Residence: ----------------------------------------- 
6- Complains: Yes,: ------------ No,: ------------- 
A symptomatic 
(2) Family History: 
- Hypertension ------------------------------------------- 
- Diabetes Mellitus ------------------------------------- 
- Kidney Disease -------------------------------------- 
- Heart Disease ---------------------------------------- 
(3) Post History : 
- Hypertention ------------------------------------------ 
- Diabetes Mellitus ------------------------------------ 
- Kidney Disease --------------------------------------- 
- Malaria and malaria treatment --------------------- 
(4) Clinical Examination: 
- General condition ----------------------------------- 
- Body mass index ------------------------------------ 
- Blood pressure ------------------------------------ 
(5) Investigation: 
- Serum urea --------------------------------------- 
- Serum creatinine -------------------------------- 
- Serum cholesterol ------------------------------- 
- Serum triglyceride ------------------------------ 
- Electrolytes -------------------------------------- 
 
 
INSTRUMENTS 
System presentation: 
The vita lab analyzer is a universal system with a price 
performancerelation optimized for small and medium through put, the main 
unit of the system is the analyzer where all liquid handling and 
measurements take place. A separate computer controls the analyzer unit, 
collects raw data and provides the user interface. A cooling unit permits the 
system to operate in such a way that it ensure the precision of all on board 
parameters. 
Analyzer unit: 
The freely programmable analyzer can be used for in vitro diagnosis 
of serum, plasma, CSF and urine. With a maximum through put of 180 
photo metric tests per hour in the mono mode or 133 tests per hour in the 
Dual mode. Up to 26 parameters can be determined selectively for one 
patient. Thirty two parameters can be loaded on to the respective positions of 
the reagent rotor. 
A total of 60 tests and 15 controls can be programmed per 
programmable reagent disc. Up to 3 controls can be assigned to each test. 
The required reagent is pippetted by the reagent arm. Volumes 
between 110Ml and 399Ml are possible for reagent I. Reagent 2 may be 
pippetted with volumes between 10 and 180 Ml. 
 
Including the sample material, volumes between 220MI and 400MI 
are allowed. The reagent arm is equipped with a heating element to warm up 
the cooled reagent prior to use. The reagent needle is rinsed inside and 
outside after each pipetting process. Subsequently to pipetting of the sample 
to the prepared reagent, liquids are mixed with the sample needle. 
The sample needle is also rinsed inside and outside after each 
pipetting process. After pipetting of reagent 2, a new mixing process is 
performed, using the reagent needle. The needle is then rinsed. 
Fifty one patient samples can be positioned in one loading operation 
as soon as all test for a sample are completed, the sample can be removed 
from the sample rotor and replaced by a new sample.The system 
automatically provides a printout of result and evaluations. 
During testing unused positions on the reagent rotor must be covered 
with the supplied caps to ensure optimum cooling and avoid water of energy. 
The caps also prevent evaporation of the reagents. Incubation and 
measurement are carried out on the reaction or cuvettes (path length 7mm, 
minimum volume 220 MI) are available, incubation is performance  at 37Co. 
Maximum incubation time is 11.5 minutes. 
Computer control: 
An external computer provides the user interface to the analyzer unit. 
The operation software is windows based in order to reduce the work 
expenditure to a minimum. Test and sample data can be entered via the 
keyboard or a barcode reader connected to the computer. All test results are 
saved on the external computer and can be printed on a printer to his 
computer. 
Entering sample data and test requests: 
The request samples mean contains all functions required for test 
requests and entry or assignment of patient samples, with a minimum of 
complexity and time you can manually enter sample and patient specific data 
and request the designated tests. Recorded samples can later be edited or 
deleted. If needed, the system prints a work list. Define the type of sample in 
this field, after pressing enter or clicking on the arrow, a drop- down list 
opens with the choices available. 
The type of sample needed can be selected as: 
Normal (normal patient sample), state (emergency sample), pediatrics 
(sample of children and teenagers are labeled pediatric), control (requests 
labeled with control are recognized by the system as controls), Calibrator (a 
request labeled calibrator is used to calibrate tests) and blank (One position 
on the inner ring of the rotor is research for the reagent blank measurement). 
In accordance with the programming made in the TEST 
PROGRAMMING menu, the screen displays a variable number of tests. 
The incoming results of each sample and test can be checked and if 
necessary validated in the EVALUATE SAMPLE menu. In the graphic 
mode the results of a dichromatic endpoint test, run in the DUAL MODE, is 
displayed. Six points are displayed by the system. 
Quality control: 
The quality control menu provides an over view of all measured 
control data. You can select one of the up to three after selection of control 
and corresponding test, you can check the test in the graphic mode, e.g. for 
stability, no graphic representation is displayed for cut off tests, test results 
can be switch directly to PROGRAM CONTROL to change assignment of 
control and to quality control which can even be called up during a 
measurement. 
Elical Calibration: 
Principle: 
Elical, a calibrator for automated system, is used for the calibration of 
clinical chemistry analysis. Elical is a lyophilized calibration serum. 
Reagent(1) is freezed dried based on human serum and reagent (2) solvent. 
Preparation: 
Carefully open the reagent (1)avoiding the loss of freeze dried 
powdered and pipette exactly 3 ml of solvent Reagent (2). Carefully close 
the bottle and dissolve the contents completely by occasional gentle swirling 
with 30 minutes avoiding the formation of foam. 
Stability of reagent: 
Prior to reconstitution, when stored at 2.8°C and protected from light, 
the reagents 1 and 2 are stable until the expiry date stated on the label. 
After reconstituting stability of components in reconstituted 
calibrator: 4 hours at 25°C, 2 days at 4°C and 1 month at - 20°C (only freeze 
once). 
 
Values: 
The calibration values were determined under strictly standardized 
conditions. The concentrations of the components are lot- specific. 
          Calibration curve can be drawn if three or more standards (maximum 
9) are used for calibration procedure. By means of this calibration curve the 
instrument will calculate a concentration from absorbance results. The 
values of the standards must be programmed in the program calibrator 
screen. 
Calculated results: 
The results calculated test are not performed on the analyzer but are 
derived from applying a calculated test formula to the results of the tests that 
are actually performed on the analyzer. Up to 10 formulas can be defined 
calculated results are not used for quality control. 
Flame photometer: 
One of the most important instrument that is used to estimate 
electrolyte. It has many types and the most important is flame emission 
photometry (Flame photometry). It is used to estimate electrolyte in solution. 
General principle: 
After preparation of solution from serum the solution is sprayed as 
fine  droplets into the flame. The metal emits radiation or light the color of 
flame is changed. By the characterizing of metal emission light, the light 
wavelength corresponding to element being analyzed is selected by filter or 
spectrophotometer or prism. The light is allowed to fall into photocell which 
convert light current and detector (to measure current) and this light is 
proportional to concentration of element being analyzed. 
 
 
REFERENCE VALUES 
 
Reference values of serum triglyceride: 
Male   60-165 mg/dL 
0.60-1.65 g/L 
                  0.68 - 1.88 mmol/L  
Female  40 - 140 mg/ dL 
0.40 -1.40 g/L 
0.46 - 1.60 mmol/L 
Reference values of serum cholesterol: 
150 -260 mg/dL 
1.5 - 2.6 g/L 
3.87 - 6.71 mmol/L 
Reference values of serum of Na + and K+: 
Normal serum Na+= 136-149mmol/L 
Normal serum K+: = 3.8 - 5.0) mmol/L 
Low K+ STD = 5.0 mmol/L 
High K+ STD 7.0 mmol/L 
Low Na+STD = 140 mmol/L 
High Na+ STD = 160 mmol/L 
 
Reference values of serum urea: 
15 - 50 mg/dL 
0.15 – 0.50 g/L 
         2.50 - 8.33 mmol/L 
Reference values of serum creatinine: 
6 - 13 mg/dL 
0.6 - 1.3 g/L 
53 - 115 m mol/L 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

